Type 1 diabetes patients who received once-daily MYL-1501D, Mylan's insulin glargine follow-on drug, had a 0.14% and 0.21% mean A1C change from baseline at 24 and 52 weeks, respectively, compared with 0.11% and 0.25% among those who were given once-daily reference insulin glargine combined with mealtime insulin lispro, according to a study in Diabetes, Obesity and Metabolism. Researchers evaluated 558 patients from the INSTRIDE 1 study and found that MYL-1501D was well-tolerated and did not cause any significant or new safety issues.
Study shows efficacy of insulin glargine follow-on as diabetes treatment
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.